)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Alterity Therapeutics
Alterity Therapeutics (ATH) investor relations material
Alterity Therapeutics Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary29 Apr, 2026
Executive summary
Achieved alignment with the FDA on key elements of the planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA), with End-of-Phase 2 meeting on track for mid-2026.
Presented new Phase 2 data at the American Academy of Neurology, showing consistent efficacy of ATH434 in slowing disease progression in MSA.
Strengthened leadership with the appointment of Dr. Daniel Claassen as Chief Medical Advisor and Ms. Ann Cunningham as Non-Executive Director.
Engaged in ongoing strategic collaboration discussions with pharmaceutical companies for ATH434.
Financial highlights
Cash and cash equivalents of A$44.53 million as of 31 March 2026.
Operating cash outflows for the quarter were A$4.73 million.
Net cash from financing activities for the quarter was A$19.17 million.
Estimated 9.4 quarters of funding available based on current cash burn.
Outlook and guidance
On track for End-of-Phase 2 FDA meeting for ATH434 in mid-2026, supporting readiness for Phase 3 pivotal trial.
Strong cash position expected to support regulatory, clinical, and commercial objectives.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alterity Therapeutics
- ATH434 slowed MSA progression by up to 48% in phase II, supporting a pivotal phase III trial in 2026.ATH
KOL event28 Apr 2026 - Net loss widened to A$19.1M as R&D spending rose; cash reserves at A$12.6M, equity raise planned.ATHH2 202427 Mar 2026
- ATH434 showed strong Phase 2 efficacy in MSA, narrowing losses and boosting cash reserves.ATHH2 202527 Mar 2026
- ATH434 slowed MSA progression in phase II, with global phase III and $2.4B peak sales projected.ATHNWR Virtual Healthcare Conference25 Mar 2026
- Revenue up 717% and net loss widened 34% as ATH434 advanced toward Phase 3 for MSA.ATHH1 202626 Feb 2026
- ATH434 improved daily living in 43% of advanced MSA patients, with strong biomarker support.ATHStudy Update3 Feb 2026
- ATH434 slowed MSA progression, reduced brain iron, and was well tolerated in phase II results.ATHStudy Result9 Jan 2026
- ATH-434 slowed MSA decline in phase II, with phase III and FDA engagement set for next year.ATHBell Potter Healthcare Conference 202519 Nov 2025
- ATH434's Phase 2 success and A$54.56M cash position set the stage for Phase 3 and global growth.ATHQ1 2026 TU31 Oct 2025
Next Alterity Therapeutics earnings date
AGM 202629 May, 2026
Alterity Therapeutics
Next Alterity Therapeutics earnings date
AGM 202629 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage